Skip to main content

Recombinant Mouse VSTM2A His-tag Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 2283-VT

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
2283-VT-050

Key Product Details

Source

NS0

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Mouse myeloma cell line, NS0-derived mouse VSTM2A protein
Ser25-Ala252, with a C-terminal 6-His tag

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ser25

Predicted Molecular Mass

26 kDa

SDS-PAGE

35-44 kDa, reducing conditions

Activity

Measured by its ability to inhibit anti-CD3 antibody induced IFN-gamma secretion by human peripheral blood mononuclear cells (PBMC).
The ED50 for his effect is 2-12 μg/mL.

Scientific Data Images for Recombinant Mouse VSTM2A His-tag Protein, CF

Recombinant Mouse VSTM2A His-tag Protein SDS-PAGE

Recombinant Mouse VSTM2A His-tag Protein SDS-PAGE

2 μg/lane of Recombinant Mouse VSTM2A was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 35-44 kDa.

Formulation, Preparation and Storage

2283-VT
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.

Background: VSTM2A

V-set and transmembrane domain-containing protein 2A (VSTM2A) is a secreted glycoprotein that is expressed by committed preadipocytes. N-linked glycosylation is crucial for its secretion, but not for preadipocyte cell differentiation activity. It is expressed during adipocyte development and its over-expression promotes adipogenesis (1). VSTM2A is highly expressed in the brain and Vstm2a was identified as an enigmatic gene that is highly produced in mouse brain (1, 2). A positive association has been observed between Vstm2a and Pparg2. PPAR gamma2 indirectly promotes Vstm2a expression in preadipocytes by amplifying adipogenic commitment, while VSTM2A promotes Pparg2 expression by activating BMP signaling (1, 3). VSTM2A is synthesized as a precursor protein that contains a 24 amino acid (aa) signal sequence followed by the VSTM2A domain. The mouse VSTM2A shares 78% and 99% aa sequence identity with human and rat VSTM2A, respectively. Adipogenic commitment was uninhibited by over-expression of VSTM2A lacking a signal peptide for secretion, suggesting that secreted VSTM2A is not involved in adipogenic commitment in vitro. While the exact role secreted VSTM2A plays is unknown, it is suggested it may modulate angiogenesis or neurogenesis due to its expression in the brain and near blood vessels, and the need for adipose tissue to develop alongside blood vessels and neural tissue (1, 4). Our data shows that mouse VSTM2A inhibits anti-CD3 induced IFN-gamma secretion in Human T cells.

References

  1. Secco, B. et al. (2017) Cell Rep. 18:93.
  2. Pandey, A.K. et al. (2014) PloS One. 9:e88889.
  3. Berry, D.C. et al. (2013) Development. 140:3939.
  4. Nishimura, S. et al. (2007) Diabetes. 56:1517.

Long Name

V-Set And Transmembrane Domain Containing 2A

Alternate Names

VSTM2

Entrez Gene IDs

222008 (Human); 211739 (Mouse); 689106 (Rat)

Gene Symbol

VSTM2A

UniProt

Additional VSTM2A Products

Product Documents for Recombinant Mouse VSTM2A His-tag Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Mouse VSTM2A His-tag Protein, CF

For research use only

Loading...
Loading...
Loading...